S-substituted 1,3,7-trialkyl-xanthine derivatives

Details S-substituted 1,3,7-trialkyl-xanthine derivatives S-substituted 1,3,7-trialkyl-xanthine derivatives

1994-11-07

1999-01-19

Berch, Mark L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

544229, 544267, 544271, 544272, 544273, C07D47312, C07D47306, A61K 3152

Patent

active

058614052

ABSTRACT:
The present invention provides 8-substituted 1,3,7-trialkylxanthines useful as A.sub.2 -selective adenosine receptor antagonists and compositions comprising such compounds. Examples of the 8-substituted 1,3,7-trialkyl xanthines include: ##STR1## In compound (a), R.sub.1, R.sub.3, and R.sub.7 are methyl and X is one to three substituents, which may be the same or different and selected from the group consisting of amino, C.sub.1 -C.sub.4 alkylcarbonylamino, carboxy C.sub.2 -C.sub.4 alkylcarbonylamino, halo, C.sub.1 -C.sub.3 alkyloxy, amino C.sub.1 -C.sub.4 alkyloxy, C.sub.1 -C.sub.4 alkyloxy carbonylamino, amino C.sub.1 -C.sub.4 alkenyloxy, isothiocyanato, and diazonium tetrafluoroborate. In compound (b), R.sub.1, R.sub.3, and R.sub.7 are methyl, R.sub..beta. is hydrogen or methyl, and X is selected from the group consisting of R, C(.dbd.O)OR, and C(.dbd.O)NH--R, wherein R is a C.sub.1 -C.sub.6 alkyl.

REFERENCES:
patent: 2840559 (1958-06-01), Krantz, Jr. et al.
patent: 3309271 (1967-03-01), Georges et al.
patent: 3624215 (1971-11-01), Stein
patent: 3624216 (1991-11-01), Stein
patent: 3641010 (1972-02-01), Schweiss et al.
patent: 4120947 (1978-10-01), Diamond
patent: 4297494 (1981-10-01), Groman et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4397779 (1983-08-01), Groman et al.
patent: 4546182 (1985-10-01), Kjellin et al.
patent: 4548820 (1985-10-01), Regnier et al.
patent: 4558051 (1985-12-01), Sunshine et al.
patent: 4567183 (1986-01-01), Sunshine et al.
patent: 4593095 (1986-06-01), Snyder et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4755517 (1988-07-01), Bruns et al.
patent: 4769377 (1988-09-01), Snyder et al.
patent: 4783530 (1988-11-01), Rzeszotarski et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4883801 (1989-11-01), Nathanson
patent: 4904472 (1990-02-01), Belardinelli et al.
patent: 4981857 (1991-01-01), Daluge et al.
patent: 5015647 (1991-05-01), Daluge et al.
patent: 5047534 (1991-09-01), Peet et al.
patent: 5175291 (1992-12-01), Kufner-Muhl
patent: 5270316 (1993-12-01), Suzuki
Jacobson et al., "8-(3-Chlorostyryl)caffeine (CSC) Is a Selective A.sub.2 -Adenosine Antagonist In Vitro and In Vivo,"FEBS Letters, 323 (1,2), 141-144 (May 1993).
Jackson et al., J. Pharmacol. Exper. Therapeut., 267, 1304-1310 (1993).
Jacobson et al., FEBS Lett., 323, 141-144 (1993).
Jacobson et al., Chem. Abstr., 119:159968u (1993).
Ji et al., Drug Development Research, 29, 292-298 (1993).
Kanda et al., Eur. J. Pharmacol., 256, 263-268 (1994).
Baumgold et al., "Penetration of Adenosine Antagonists into Mouse Brain as Determined by Ex Vivo Binding," Biochemical Pharmacology, 43(4), 889-894 (1992).
Bruns et al., "Characterization of the A.sub.2 Adenosine Receptor Labeled 331-346 (1986).
Bruns, "Adenosine Receptors in Brain Membranes: Binding of N.sup.6 phenylxanthine," Proc. Natl. Acad. Sci. USA, 77(9), 5547-5551 (1980).
Bruns, "Adenosine Antagonism by Purines, Pteridines and Benzopteridines in Human Fibroblasts," Biochemical Pharmacology, 30, 325-333 (1981).
Cheng et al., "Relationship Between the Inhibition Constant (K.sub.1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I.sub.50) of an Enzymatic Reaction," Biochem. Pharmacol., 22, 3099-3108 (1973).
Daly, "Adeosine Receptors: Targets for Future Drugs," J. Medicinal Chemistry, 25(3), 197-207 (1982).
Daly et al., "Caffeine Analogs: Sructure-Activity Relationships at Adenosine Receptors," Pharmacology, 42, 309-321 (1991).
Erickson et al., "1,3,8-Trisubstituted Xanthines. Effects of Substitution Pattern upon Adenosine Receptor A.sub.1 /A.sub.2 Affinity," J. Med. Chem., 34, 1431-1435 (1991).
Ferre et al., "Adenosine-Dopamine Interactions in the Brain," Neuroscience, 51(3), 501-512 (1992).
Francis et al., "Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists," J. Med. Chem., 31, 1014-1020 (1988).
Griebel et al., "Behavioural Effects of Selective A.sub.2 Adenosine Receptor Antagonists, CGS 21197 and CGS 22706, in Mice." NeuroReport, 2, 139-140 (1991).
Jacobson et al., "Xanthine Functionalized Congeners as Potent Ligans at A.sub.2 -Adenosine Receptors," J. Med. Chem., 30, 211-214 (1987).
Jacobson et al., "Agonist Derived Molecular Probes for A.sub.2 Adenosine Receptors," J. Molecular Recognition, 2(4), 170-178 (1989).
Jacobson et al., "Electrophilic Derivatives of Purines as Irreversible Inhibitors of A.sub.1 Adenosine Receptors ," J. Med. Chem., 32 1043-1051 (1989).
Jacobson et al., "Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential," J. Med. Chem.,35, 407-422 (1992).
Jacobson et al., "Chemical Modification and Irreversible Inhibition of Striatal A.sub.2a Adenosine Receptors," Molecular Pharmacology, 42, 123-133 (1992). Receptor Agonist Directly Labels A.sub.2 Receptors in Rat Brain," J. Pharmacol. Exp. Therap. 251, 888-893 (1989).
Lohse et al., "Separation of Solubilized A.sub.2 Adenosine Receptors of Filtration," Naunyn Schmiedeberg's Archives of Pharmacology, 337, 64-68 (1988).
Nikodijevic et al., "Behavioral Effects of A.sub.1 -and A.sub.2 -Selective Adenosine Agonists and Antagonists: Evidence for Synergism and Antagonism," J. Pharmacology, 259(1), 286-294 (1991). of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants," J. Med. Chem., 33, 2240-2254 (1990).
Schiffmann et al., "Adenosine A.sub.2a Receptor Expression in Stariatal Neurons: Implications for Basal Ganglia Pathophysiology," Drug Development Research, 28, 381-385 (1993).
Schwabe et al., "Characterization of Adenosine Receptors in Rat Brain by Arch. Pharmacology, 313, 179-187 (1980).
Shamim et al., "Effects of 8-Phenyl and 8-Cycloalkyl Substituents on the Activity of Mono-, Di-, and Trisubstituted Alkylxanthines with Substitution at the 1-, 3-, and 7-Positions," J. Med. Chem., 32, 1231-1237 (1989).
Shimada et al., "(E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxy-styry)xanthines: Potent and Selective Adenosine A.sub.2 Antagonists," J. Med. Chem., 35, 2342-2345 (1992).
Snyder et al., "Adenosine Receptors and Behavioral Actions of Methylxanthines," Proc. Natl. Acad. Sci. USA ., 78(5), 3260-3264 (1981).
Stehle et al., "Molecular Cloning and Expression of the cDNA for A Novel A.sub.2 -Adenosine Receptor Subtype," Mol. Endocrinol., 6, 384-393 (1992).
Stone et al., "Species Differences in High-Affinity Adenosine A.sub.2 Binding Sites in Striatal Membranes from Mammalian Brain," Drug Development Research, 15, 31-46 (1988).
Ueeda et al., "2-Aralkoxyadenosines: Potent and Selective Agonists at the Coronary Artery A.sub.2 Adenosine Receptor," J. Med. Chem., 34, 1340-1344 (1991).
Ueno et al., "A.sub.1 and A.sub.2 Adenosine Receptor Regulation of Erythropoietin Production," Life Sciences, 43, 229-237 (1988).
Ukena et al., "Functionalized Congeners of 1,3-Dipropyl-8-Phenylxanthine: Potent Antagonists for Adenosine Receptors that Modulate Membrane Adenylate Cyclase in Pheochromocytoma Cells, Platelets and Fat Cells," Life Sciences, 38, 797-807 (1986).
Ukena et al., "Analogs of Caffeine: Antagonists with Selectivity for A.sub.2 Adenosine Receptors," Life Sciences, 39, 743-750 (1986).
Ukena et al., "Species Differences in Structure-Activity Relationships of Adenosine Agonists and Xanthine Antagonists at Brain A1 Adenosine Receptors," FEBS Letters, 209 (1), 122-128 (1986).
van Galen et al., "Adenosine A.sub.1 and A.sub.2 Receptors: Structure-Function Relationships," Medicinal Research Reviews, 12(5), 423-471 (1992).
Leff, BioWorld Today vol. 6, #7, p. 1,4 (Jan. 12, 1995).
"Goodman and Gilman's Pharmacological Basis of Therapentics, 7th Edition" (1985) p. 589, 598-601 Jacobson, Biochem. Pham. 41, 1399 (1991).
Katzung, "Basic and Clinical Pharmacology, 3.sup.rd Edition" (1987) pp. 20-21.
Craig, BioWorld Today, Oct. 18, 1994. p 1.

Affiliated with

Also associated with

Rating

S-substituted 1,3,7-trialkyl-xanthine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with S-substituted 1,3,7-trialkyl-xanthine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S-substituted 1,3,7-trialkyl-xanthine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1246869